GE Healthcare (NYSE: GE) sold Clarient, Inc. and its wholly owned subsidiary Clarient Diagnostic Services, Inc., which provides comprehensive cancer diagnostic testing to hospitals, physicians and the pharmaceutical industry. The acquirer was NeoGenomics, Inc. (NASDAQ: NEO), which, together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing labs providing genetic and molecular services. The price, totaling $275,200,000, consists of $80 in cash, $110 million in preferred stock at $7.50 per share, and 15 million shares of NeoGenomics common stock ($85.2 million, based on the prior-day closing price of $5.68 per share). In effect, GE Healthcare will own 32% of NEO.
Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
